Communiqués Cipher Pharmaceuticals Inc.

Actions

CPH

CA17253X1050

Produits pharmaceutiques

Marché Fermé - Toronto S.E. 21:59:59 22/09/2026			Varia. 5j.	Varia. 1 janv.
14,53 ^CAD	+0,76%		-0,21%	-3,52%

21/09	Cipher Pharmaceuticals Inc. annonce la nomination de Rajiv De Silva au conseil d'administration, avec effet au 21 septembre 2026	CI
01/09	La justice américaine confirme la propriété de Cipher Pharmaceuticals sur certaines données cliniques liées à l'Absorica	MT

Communiqués

21/09	Cipher Pharmaceuticals Announces the Appointment of Rajiv De Silva to its Board of Directors	AQ
01/09	Cipher Pharmaceuticals Receives Favourable Decision Confirming Arbitration Award	AQ
11/08	Cipher Pharmaceuticals Reports Second Quarter 2026 Results	AQ
31/07	Cipher Pharmaceuticals Schedules Q2 2026 Earnings Release and Conference Call	AQ
06/07	Cipher Pharmaceuticals and the pan-Canadian Pharmaceutical Alliance (pCPA) Sign Letter of Intent for Public Drug Plan Coverage of Epuris®	AQ
18/06	Cipher Pharmaceuticals Announces Results of Annual General Meeting of Shareholders	AQ
08/05	Cipher Pharmaceuticals : Quarterly Report Q1 2026	PU
07/05	Cipher Pharmaceuticals Reports First Quarter Results	AQ
01/05	Cipher Pharmaceuticals Announces Normal Course Issuer Bid	AQ
29/04	Cipher Pharmaceuticals Schedules Q1 2026 Earnings Release and Conference Call	AQ
08/04	Cipher Pharmaceuticals : AIF 2025	PU
12/03	Cipher Pharmaceuticals : Annual Report 2025	PU
12/03	Cipher Pharmaceuticals Reports Fourth Quarter Results and Full Year 2025 Record Revenue and Earnings	AQ
04/03	Cipher Pharmaceuticals Schedules Q4 & Fiscal 2025 Earnings Release and Conference Call	AQ
28/01	Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad)	AQ
06/11	Cipher Pharmaceuticals : Quarterly Report Q3 2025	PU
06/11	Cipher Pharmaceuticals Reports Third Quarter 2025 Results	AQ
29/10/25	Cipher Pharmaceuticals Schedules Q3 2025 Earnings Release and Conference Call	AQ
14/10/25	Cipher Pharmaceuticals Receives Successful Arbitration Award	AQ
26/08/25	Cipher Pharmaceuticals Announces the Passing of Director Mr. Harold Wolkin	AQ
08/08/25	Cipher Pharmaceuticals : Quarterly Report Q2 2025	PU
07/08/25	Cipher Pharmaceuticals Reports Second Quarter 2025 Results, Including Record Revenue	AQ
29/07/25	Cipher Pharmaceuticals Schedules Q2 2025 Earnings Release and Conference Call	AQ
13/06/25	Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders	AQ
08/05/25	Cipher Pharmaceuticals Reports First Quarter 2025 Results, and Announces $15 Million Debt Repayment	AQ